Filtered By:
Drug: Lipitor

This page shows you your search results in order of date. This is page number 4.

Order by Relevance | Date

Total 101 results found since Jan 2013.

Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial
ConclusionAtorvastatin 40mg daily was safe and resulted in significantly greater reduction of LDLc than placebo in patients with RA. The 40% (adjusted) CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 14, 2019 Category: Rheumatology Authors: George D. Kitas, Peter Nightingale, Jane Armitage, Naveed Sattar, Jill J.F. Belch, Deborah P.M. Symmons, The TRACE RA consortium, George Kitas, Jill Belch, Deborah Symmons, Hawys Williams, Shobna Vasishta, Rebecca Storey, Peter Nightingale, Tags: Full Length Source Type: research

Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis and network meta-analysis of randomized trials with 94,283 participants
ConclusionsAll statins showed statistically significant risk reduction of CVD and all-cause mortality in primary prevention populations while increasing the risk for some harm risks. However, the benefit-harm profile differed by statin type. A quantitative assessment of the benefit-harm balance is thus needed since meta-analyses alone are insufficient to inform whether statins provide net benefit.
Source: American Heart Journal - January 11, 2019 Category: Cardiology Source Type: research

Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies
AbstractRecent studies have shown a high prevalence of dyslipidemia in patients with systemic autoimmune myopathies (SAM). However, little is known about the safety of the use of statins in these patients, and this gap in research motivated the accomplishment of the present study. In a retrospective cohort study conducted from 2004 to 2018, 250 patients with SAM were evaluated, and 24 patients had stable forms of SAM (16 dermatomyositis, 1 polymyositis and 7 antisynthetase syndrome) but had dyslipidemia and had received statins. Patients with clinically amyopathic dermatomyositis, immune-mediated necrotizing myopathy, derm...
Source: Rheumatology International - December 5, 2018 Category: Rheumatology Source Type: research

PGC-1 β modulates statin-associated myotoxicity in mice.
PGC-1β modulates statin-associated myotoxicity in mice. Arch Toxicol. 2018 Dec 03;: Authors: Singh F, Zoll J, Duthaler U, Charles AL, Panajatovic MV, Laverny G, McWilliams TG, Metzger D, Geny B, Krähenbühl S, Bouitbir J Abstract Statins inhibit cholesterol biosynthesis and lower serum LDL-cholesterol levels. Statins are generally well tolerated, but can be associated with potentially life-threatening myopathy of unknown mechanism. We have shown previously that statins impair PGC-1β expression in human and rat skeletal muscle, suggesting that PGC-1β may play a role in statin-induced myopathy. PGC-...
Source: Archives of Toxicology - December 3, 2018 Category: Toxicology Authors: Singh F, Zoll J, Duthaler U, Charles AL, Panajatovic MV, Laverny G, McWilliams TG, Metzger D, Geny B, Krähenbühl S, Bouitbir J Tags: Arch Toxicol Source Type: research

To study the effect of high dose Atorvastatin 40mg versus 80mg in patients with dyslipidemia.
CONCLUSION: This study concluded that both doses of atorvastatin (40 & 80mg) are equally efficacious in improving dyslipidemia but higher dose leads to more incidence of myalgia. PMID: 30595326 [PubMed - in process]
Source: Indian Heart J - December 1, 2018 Category: Cardiology Authors: Agrawal D, Manchanda SC, Sawhney JPS, Kandpal B, Jain R, Mehta A, Mohanty A, Passey R, Makhija A, Sharma MK Tags: Indian Heart J Source Type: research

Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects.
CONCLUSION: Our results clearly demonstrate that the frequency of CYP3A5*3 splicing variant is higher in myopathy group than in the tolerant group. We did not find significant association of genetic polymorphisms in CYP3A5, COQ, and SLCO1B1 with atorvastatin- or rosuvastatin-induced myopathy. PMID: 30595243 [PubMed - in process]
Source: Indian Heart J - December 1, 2018 Category: Cardiology Authors: Ramakumari N, Indumathi B, Katkam SK, Kutala VK Tags: Indian Heart J Source Type: research

Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase
ConclusionsThe number of IMNM reports has increased in recent years. IMNM associated with statin treatment seems to occur worldwide. Most IMNM cases were reported with atorvastatin. No dose dependency of statin-associated IMNM pathogenesis was identified.
Source: European Journal of Clinical Pharmacology - November 15, 2018 Category: Drugs & Pharmacology Source Type: research

Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects
ConclusionOur results clearly demonstrate that the frequency of CYP3A5*3 splicing variant is higher in myopathy group than in the tolerant group. We did not find significant association of genetic polymorphisms in CYP3A5, COQ, and SLCO1B1 with atorvastatin- or rosuvastatin-induced myopathy.
Source: Indian Heart Journal - September 7, 2018 Category: Cardiology Source Type: research

Impact of pharmacogenetics on statin-induced myopathy in south Indian subjects
ConclusionOur results clearly demonstrates that the frequency of CYP3A5*3 splicing variant is higher in myopathy group as compared to tolerant group. We did not find significant association of genetic polymorphisms in CYP3A5, COQ and SLCO1B1 with atorvastatin or rosuvastatin induced myopathy.
Source: Indian Heart Journal - August 10, 2018 Category: Cardiology Source Type: research

Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins
AbstractThe introduction of ticagrelor, one of the first directly-acting oral antiplatelet drugs, provided new possibilities in the prevention of thrombotic events in patients with acute coronary syndromes (ACS). Current guidelines recommend ticagrelor in dual antiplatelet therapy with aspirin over clopidogrel for prevention of stent thrombosis in patients with ACS. Moreover, in the management of ACS, lipid-lowering treatment with high-intensity statin therapy is advised for secondary prevention of cardiovascular events over the long term. Despite the apparent advantages of combined antiplatelet and lipid-lowering treatmen...
Source: Drugs - July 12, 2018 Category: Drugs & Pharmacology Source Type: research

Efficacy and safety of Zhibitai in combination with atorvastatin for lipid lowering in patients with coronary heart disease.
Conclusion: Overall the two groups have similar lipid regulation efficacy. Zhibitai plus low dose Atorvastatin is more efficacious in lowering TG in patients with TG > 203.72 mg/dL at week 8. There are fewer side effects in Zhibitai plus low dose Atorvastatin group. Long term follow up is required to evaluate cardiovascular outcomes. PMID: 29507705 [PubMed]
Source: Oncotarget - March 8, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Effects of a series of acidic drugs on L-lactic acid transport by the monocarboxylate transporters MCT1 and MCT4.
CONCLUSION: This inhibition may cause an accumulation of intracellular L-lactic acid leading to acidification and muscular disorders. PMID: 29521223 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Biotechnology - March 7, 2018 Category: Biotechnology Authors: Leung YH, Belanger F, Lu J, Turgeon J, Michaud V Tags: Curr Pharm Biotechnol Source Type: research

To study the effect of high dose Atorvastatin 40  mg versus 80 mg in patients with dyslipidemia
Conclusion This study concluded that both doses of atorvastatin (40 & 80 mg) are equally efficacious in improving dyslipidemia but higher dose leads to more incidence of myalgia.
Source: Indian Heart Journal - February 9, 2018 Category: Cardiology Source Type: research

Interaction of deoxyschizandrin and schizandrin B with liver uptake transporters OATP1B1 and OATP1B3.
Abstract 1. Deoxyschizandrin and schizandrin B have diverse pharmacological effects, including hepatoprotective activity. We aim to study their hepatic uptake and their effects on the hepatic uptake of other clinical drugs mediated by OATP1B1 and OATP1B3. 2. Deoxyschizandrin exhibited a high affinity for OATP1B1 with Km of 17.61 ± 0.43 μM but a low affinity for OATP1B3. Similarly, schizandrin B also showed a strong affinity for OATP1B1 with Km of 18.45 ± 1.23 μM but a weak affinity for OATP1B3. 3. Atorvastatin and rifampicin could inhibit the uptake of deoxyschizandrin and schizandrin B mediated by OATP1B1. 4....
Source: Xenobiotica - February 6, 2018 Category: Research Authors: Lu Y, Hu Q, Chen L, Zhang H, Huang S, Xiong Y, Xia C Tags: Xenobiotica Source Type: research

The pharmacodynamic and clinical trial evidence for statin dose
Abstract Statin doses around estimated effective dose 50 (ED50) can reduce myocardial infarction by over 25% and mortality by around 10%. Being a competitive enzyme inhibitor, statin efficacy plateaus at doses that are multiples above the ED50, whilst on‐ and off‐target adverse events increase in number and severity with increasing dose. For example, myopathy has been shown to increase by up to 29‐fold and liver dysfunction by up to 9‐fold as statin dose is increased. Doses of up to 40‐fold ED50 have been promoted, but above 5‐fold ED50, for example 10 mg of atorvastatin, there is no randomised controlled clini...
Source: British Journal of Clinical Pharmacology - February 1, 2018 Category: Drugs & Pharmacology Authors: Simon B. Dimmitt, Hans G. Stampfer, John B. Warren Tags: REVIEW Source Type: research